Sector: Health Care
Director information for GLAUKOS CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Aimee S. Weisner | Former Corporate Vice President and General Counsel; Independent Director | 57 | ["Former Corporate Vice President and General Counsel, Edwards Lifesciences Corporation","Corporate Vice President and General Counsel, Edwards Lifesciences Corporation (2011 to 2019)","Legal Advisor to Public Pharmaceutical and Medical Device Companies (2009 to 2010)","Executive Vice President, Administration and Secretary, Advanced Medical Optics, Inc. (2002 to 2009)","Vice President, Assistant General Counsel and Assistant Secretary, Allergan, Inc. (1998 to 2002)","in-house legal and compliance experience with medical device companies","understanding of regulatory and reimbursement issues","intellectual property","corporate governance","risk management","corporate transactions","human resources","internal audit"] | ["Audit"] | 2026 |
| David F. Hoffmeister | Former Senior Vice President and Chief Financial Officer; Independent Director; Chair | 71 | ["Senior Vice President and Chief Financial Officer, Life Technologies Corporation","Chief Financial Officer, Invitrogen Corporation","Senior Partner, McKinsey & Company","Leader, McKinsey & Company, North American Chemical Practice","strong finance background","experience as a chief financial officer of a global biotechnology company","public company board experience","experience in the healthcare and chemical industries","private equity experience","strategy and organization experience"] | ["Compensation,NominatingandGovernance","Audit"] | 2026 |
| Denice M. Torres | Chief Executive Officer; Independent Director; CEO of a healthcare industry change management firm | 66 | ["Founder and Chief Executive Officer, The Ignited Company, a consulting firm (2017 to current)","Chief Strategy and Transformation Officer, Johnson & Johnson, Global Medical Device Business (2015 to 2017)","President, Johnson & Johnson McNeil Consumer Healthcare (2011 to 2015)","President, Johnson & Johnson Janssen Pharmaceuticals, Neuroscience (2009 to 2011)","Vice President Positions, Johnson & Johnson (2004 to 2009)","Various Executive Positions, Eli Lilly and Company (1990 to 2004)","Founder of The Mentoring Place, a nonprofit organization offering free executive mentoring to help women achieve their career goals","extensive experience running large businesses in the pharmaceutical, consumer health and medical device industries","executive management of global commercialization, quality, strategy and marketing","CEO of a healthcare industry change management firm focused on leadership, diversity, equity and inclusion and culture"] | ["Compensation","Nominating and Governance"] | 2026 |
| Gilbert H. Kliman, M.D. | Independent Director | 67 | ["Partner, InterWest Partners, a venture capital firm (1996 to 2015)","Managing Partner (2016 to current)","Investment Manager, Norwest Venture Partners (1995 to 1996)","Associate, TA Associates (1989 to 1992)","Board-certified ophthalmologist","Completed a retina research fellowship at Massachusetts Eye and Ear Infirmary","Residency training at Wills Eye Hospital"] | ["Compensation","Nominating and Governance"] | 2026 |
| Gilbert H. Kliman, MD | Managing Partner | 67 | [] | [] | 2026 |
| Joseph E. Gilliam | President and Chief Operating Officer | ["B.S. in accounting from the Kelly School of Business at Indiana University","served as Chief Financial Officer and Senior Vice President, Corporate Development","experience in accounting, financing, business development, investor relations, regulatory, internal audit","Managing Director in Healthcare Investment Banking at JPMorgan Chase & Co.","experience in mergers and acquisitions, public equity offerings, bank lending, bond offerings","started career at PricewaterhouseCoopers LLP"] | ["audit","compensation"] | 2026 | |
| Leana S. Wen, M.D. | [] | [] | 2026 | ||
| Leana S. Wen, MD | Emergency Physician and Adjunct Associate Professor; Director | 43 | ["Adjunct Associate Professor, George Washington University","Adjunct Associate Professor, George Washington University (2019 to current)","Contributing Columnist, The Washington Post (2020 to current)","Medical Analyst and Health Contributor, CNN (2020 to current)","Senior Fellow, Brookings Institute (2020-current)","President, Planned Parenthood (2018 to 2019)","Health Commissioner, City of Baltimore (2015 to 2018)","Director, Patient-Centered Care Research, Department of Emergency Medicine, George Washington University (2013 to 2015)","Board-certified Emergency Room Physician","Member of more than ten nonprofit boards, including serving as the chair of Behavioral Health Systems Baltimore","Global health fellow at the World Health Organization","Consultant with the China Medical Board","Nonresident senior fellow at the Brookings Institution"] | ["Audit"] | 2026 |
| Marc A. Stapley | Chief Executive Officer | 56 | ["Chief Executive Officer, Veracyte, Inc. (2021 to current)","Chief Executive Officer, Helix, Inc. (2019 to 2021)","Executive Vice President, Strategy and Corporate Development, Illumina, Inc. (2017 to 2019)","Chief Administrative Officer, Illumina, Inc. (2015 to 2017)","Senior Vice President and Chief Financial Officer, Illumina, Inc. (2012 to 2017)","Senior Vice President, Finance, Pfizer, Inc. (2009 to 2012)","Auditor, Coopers & Lybrand (1991 to 1995)","B.Sc (Honors), The University of Reading (England)"] | ["Audit","Compensation","Nominating and Governance"] | 2026 |
| Mark J. Foley | Lead Independent Director | 60 | ["Former Chief Executive Officer, Revance Therapeutics, Inc.","Chief Executive Officer, Revance Therapeutics, Inc.","Chairman, President and Chief Executive Officer, ZELTIQ Aesthetics, Inc.","Managing Director, RWI Ventures, Inc.","Various Executive Positions for United States Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention Inc., Perclose, Inc., and Ventrica, Inc."] | ["Audit","Compensation","Nominating and Governance"] | 2026 |
| Thomas W. Burns | Chairman & Chief Executive Officer; Director; CEO | 65 | ["Chief Executive Officer and Board Member, Glaukos Corporation (2002 to current)","Chairman of the Board (2021 to current)","Vice President, Global Strategy and General Manager, Refractive Surgery, Bausch & Lomb (1998 to 2000)","Senior Vice President and General Manager, Chiron Vision Corporation (1990 to 1997)","Bachelor of Arts, Yale University","Served as an entrepreneur in residence at Versant Ventures Management, LLC","building successful medical device and pharmaceutical businesses","creating successful new markets in ophthalmology","commercializing new products","extensive understanding of business, operations and strategy","significant industry experience","corporate management skills"] | [] | 2026 |
| Tomas Navratil | Chief Development Officer | ["nearly 20 years of experience in ophthalmic drug and medical device R&D and regulatory affairs","leadership at Nicox Group","general manager of Nicox Ophthalmics, Inc.","senior vice president of development at Envisia Therapeutics and Liquidia Technologies","director-level positions in drug discovery, clinical research, and medical affairs","issued multiple patents and authored publications on ocular and pulmonary drug delivery","Morehead Scholar","B.S. and Ph.D. in chemistry from the University of North Carolina at Chapel Hill"] | [] | 2026 |
